Using Plasma Jets to Deliver Cancer Medication

Plasma jets are a promising tool for killing cancerous cells by exposing them to reactive oxygen.


Newswise — COLUMBUS, Ohio, OCTOBER 21, 2019 -- Modern advances in oncology have significantly improved cancer survival rates. However, personalized treatment methods are necessary, since tumors may behave differently for different patients.

At the AVS 66th International Symposium and Exhibition in Columbus, Ohio, Cristina Canal, a researcher in the biomaterials, biomechanics and tissue engineering research group at Universitat Politècnica de Catalunya, will present cold plasmas as a promising tool for minimally invasive cancer therapy.

In her talk, Canal will discuss the benefits of using plasma jets for cancer therapy, and explain the use of different liquid media, hydrogels and their properties.

In recent years, cancer researchers have paid significant attention to the ability of plasma jets to kill cancer cells without causing damage to surrounding healthy tissue. This property has been demonstrated in a number of different types of cancer, including breast, brain and bone cancers.

Cancer cells are highly sensitive to oxidative stress, which is an excess of reactive oxygen-containing chemical species in the system. Exposure to oxidative stress can lead to the death of cancer cells.

“By providing exogenous reactive oxygen and nitrogen species from plasma-activated medium to these cells, they exceed their toxicity threshold and undergo cell death,” said Canal.

The reactive species generated by plasma-activated liquids can be stored in hydrogels, which are materials used for various biomedical applications due to their biocompatibility. The hydrogels then deliver these to the tumor.

To understand how to achieve this efficiently, Canal and her team investigated the effects of different plasma jets used in combination with various hydrogels on osteosarcoma, a common type of bone tumor prevalent in children and teenagers.

“The mechanisms of action of cold plasmas and plasma-activated media seem to be common among these different cancers,” Canal said. As a result, the researchers expect their methods might be work for other types of cancers as well.

###

Presentation: “Cold Plasma Jets, Liquids and Biomaterials for Bone Cancer Therapy,” Cristina Canal, Universitat Politècnica de Catalunya, Monday, Oct. 21, 4:40 p.m., Room B131 in the Greater Columbus Convention Center, Columbus, Ohio.

###

----------------------- MORE MEETING INFORMATION -----------------------

USEFUL LINKS

Main meeting website: https://www.avs.org/Symposium
Annual meeting program: https://www.avs.org/Symposium/Technical-Program/Divisions-Groups
Housing and travel: https://www.avs.org/Symposium/Housing-Travel

 

PRESS REGISTRATION

To request free press registration, please contact Della Miller at della@avs.org.

ABOUT AVS

AVS is an interdisciplinary, professional society with some 4,500 members worldwide. Founded in 1953, AVS hosts local and international meetings, publishes five journals, serves members through awards, training and career services programs and supports networking among academic, industrial, government, and consulting professionals. Its members come from across the fields of chemistry, physics, biology, mathematics, engineering and business and share a common interest in basic science, technology development and commercialization related to materials, interfaces, and processing. For more information about AVS, visit our website at http://www.avs.org.

###


Comment/Share

Chat now!
8.17687